Barclays PLC Iveric Bio, Inc. Transaction History

Barclays PLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 03, 2023	SELL	$26.24 - $39.63 $12.6 Million - $19.1 Million	-482,022 Reduced 67.16%	235,648 $9.27 Million
Q1 2023 May 04, 2023	BUY	$18.67 - $24.56 $9.03 Million - $11.9 Million	483,518 Added 206.5%	717,670 $17.5 Million
Q4 2022 Feb 13, 2023	SELL	$17.24 - $23.95 $1.66 Million - $2.31 Million	-96,398 Reduced 29.16%	234,152 $5.01 Million
Q3 2022 Nov 03, 2022	BUY	$9.4 - $18.59 $2.97 Million - $5.88 Million	316,278 Added 2216.07%	330,550 $5.93 Million
Q2 2022 Aug 12, 2022	SELL	$9.12 - $18.9 $3.39 Million - $7.02 Million	-371,367 Reduced 96.3%	14,272 $137,000

Q1 2022 May 16, 2022	BUY	$12.15 - $16.83 $2.93 Million - $4.06 Million	240,994 Added 166.61%	385,639 $6.49 Million
Q4 2021 Feb 14, 2022	BUY	$13.83 - $18.78 $1.41 Million - $1.91 Million	101,622 Added 236.2%	144,645 $2.42 Million
Q3 2021 Nov 09, 2021	SELL	$7.07 - $17.5 $306,625 - $758,975	-43,370 Reduced 50.2%	43,023 $698,000
Q2 2021 Aug 13, 2021	BUY	$5.69 - $7.17 $105,299 - $132,688	18,506 Added 27.26%	86,393 $544,000
Q1 2021 May 13, 2021	BUY	$5.08 - $6.89 $6,761 - $9,170	1,331 Added 2.0%	67,887 $419,000
Q4 2020 Feb 11, 2021	BUY	$5.65 - $7.66 $168,285 - $228,153	29,785 Added 81.0%	66,556 $460,000
Q3 2020 Nov 12, 2020	BUY	$4.01 - $6.29 $47,739 - $74,882	11,905 Added 47.88%	36,771 $208,000
Q2 2020 Aug 12, 2020	BUY	$3.06 - $6.6 $76,089 - $164,115	24,866 New	24,866 $127,000
Q1 2020 May 13, 2020	SELL	$2.83 - $8.44 $2 - $8	-1 Closed	0 $0
Q4 2019 Feb 10, 2020	BUY	$0.93 - $8.58 $0 - $8	1 New	1 $0

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.